31 March 2022
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation company has been notified that on 28 March 2022, Yorkshire Building Society have purchased ordinary shares ("Shares") on behalf of Stefan Macdonald (PDMR), in respect of his purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.
Enquiries:
Diaceutics PLC |
|
Nick Roberts, Chief Financial Officer |
Via Alma PR |
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) |
Tel: +44 (0)20 7710 7600 |
Ben Maddison |
|
Stewart Wallace |
|
Nick Adams |
|
|
|
Alma PR |
Tel: +44(0)20 3405 0205 |
Caroline Forde |
diaceutics@almapr.co.uk |
Kieran Breheny |
|
Matthew Young |
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
a. |
Name |
Stefan Macdonald |
|||||
2 |
Reason for notification |
|
|||||
a. |
Position/Status |
Chief Growth Officer and PDMR |
|||||
b. |
Initial notification/ Amendment |
Initial |
|||||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
a. |
Name |
Diaceutics PLC |
|||||
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £ 0.002 each
ISIN: GB00BJQTGV64 |
|||||
b. |
Nature of the transaction |
Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") |
|||||
c. |
Price(s) and volume(s) |
|
Share purchase: |
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
108.00 p |
139 |
|
|||||
|
Matched share award: |
|
|||||
|
Price(s) |
Volume(s) |
|
||||
|
108.00 p |
278 |
|
||||
|
|||||||
e. |
Date of the transaction |
Share purchase and Matched Share award: 28 March 2022 |
|||||
f. |
Place of the transaction |
Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange |
|||||